CN101842482B - 原核生物苯丙氨酸氨裂合酶的组合物及使用所述组合物的方法 - Google Patents

原核生物苯丙氨酸氨裂合酶的组合物及使用所述组合物的方法 Download PDF

Info

Publication number
CN101842482B
CN101842482B CN200880016898.4A CN200880016898A CN101842482B CN 101842482 B CN101842482 B CN 101842482B CN 200880016898 A CN200880016898 A CN 200880016898A CN 101842482 B CN101842482 B CN 101842482B
Authority
CN
China
Prior art keywords
pal
avpal
application
protein
individuality
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880016898.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101842482A (zh
Inventor
米歇尔·C·维拉德
P·A·菲茨帕特里克
E·D·卡基斯
丹尼尔·J·温特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101842482(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of CN101842482A publication Critical patent/CN101842482A/zh
Application granted granted Critical
Publication of CN101842482B publication Critical patent/CN101842482B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200880016898.4A 2007-05-25 2008-05-23 原核生物苯丙氨酸氨裂合酶的组合物及使用所述组合物的方法 Active CN101842482B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US11/807,227 2007-05-25
PCT/US2008/006661 WO2008153776A1 (en) 2007-05-25 2008-05-23 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

Publications (2)

Publication Number Publication Date
CN101842482A CN101842482A (zh) 2010-09-22
CN101842482B true CN101842482B (zh) 2014-10-22

Family

ID=39868905

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880016898.4A Active CN101842482B (zh) 2007-05-25 2008-05-23 原核生物苯丙氨酸氨裂合酶的组合物及使用所述组合物的方法

Country Status (29)

Country Link
US (1) US7534595B2 (enExample)
EP (2) EP2152868B1 (enExample)
JP (1) JP5670183B2 (enExample)
KR (2) KR101603796B1 (enExample)
CN (1) CN101842482B (enExample)
AR (2) AR066716A1 (enExample)
AU (1) AU2008263190B2 (enExample)
BR (1) BRPI0811267B8 (enExample)
CA (1) CA2687450C (enExample)
CL (1) CL2008001497A1 (enExample)
CY (2) CY1116894T1 (enExample)
DK (1) DK2152868T3 (enExample)
EA (1) EA018443B1 (enExample)
ES (1) ES2551315T3 (enExample)
HR (1) HRP20151268T1 (enExample)
HU (2) HUE025784T2 (enExample)
IL (1) IL202132A (enExample)
LT (1) LTC2152868I2 (enExample)
LU (1) LUC00133I2 (enExample)
MX (1) MX2009012453A (enExample)
MY (1) MY151413A (enExample)
NL (1) NL301011I2 (enExample)
NO (1) NO2019037I1 (enExample)
PE (1) PE20090315A1 (enExample)
PL (1) PL2152868T3 (enExample)
PT (1) PT2152868E (enExample)
SI (1) SI2152868T1 (enExample)
TW (1) TWI418633B (enExample)
WO (1) WO2008153776A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
EP2531209B1 (en) 2010-02-04 2016-04-20 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
CA2880620A1 (en) * 2012-07-27 2014-01-30 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
SG11201508598YA (en) * 2013-04-18 2015-11-27 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
DK3145536T3 (da) 2014-04-16 2022-01-03 Codexis Inc Modificeret tyrosinammoniaklyase
KR102438885B1 (ko) 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
IL263801B2 (en) 2016-07-26 2024-01-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
JP7024951B2 (ja) * 2016-08-30 2022-02-24 三菱ケミカル株式会社 変異型酵素の製造方法及び変異型アルコールアシルトランスフェラーゼ
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
NZ755628A (en) * 2017-02-13 2023-09-29 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
WO2019217513A2 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10900055B2 (en) * 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
CA3105916A1 (en) * 2018-07-12 2020-01-16 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11473077B2 (en) 2018-12-14 2022-10-18 Codexis, Inc. Engineered tyrosine ammonia lyase
CN113544268A (zh) 2018-12-20 2021-10-22 科德克希思公司 人类α半乳糖苷酶变体
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
US11987823B2 (en) 2019-08-30 2024-05-21 Societe Des Produits Nestle S.A. Engineered lipase variants
WO2021127457A1 (en) 2019-12-20 2021-06-24 Codexis, Inc. Engineered acid alpha-glucosidase variants
CA3168922A1 (en) 2020-02-04 2021-08-12 Codexis, Inc. Engineered leucine decarboxylases
US20230183712A1 (en) * 2020-02-19 2023-06-15 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用ａａｖ及治療調配物之苯酮尿症治療
JP2023539632A (ja) 2020-08-28 2023-09-15 コデクシス， インコーポレイテッド 操作されたプロテアーゼバリアント
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
US11918633B2 (en) 2021-05-19 2024-03-05 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
AU2022279241A1 (en) 2021-05-21 2023-11-30 Codexis, Inc. Engineered methionine gamma lyase variants
US20250000957A1 (en) * 2021-09-16 2025-01-02 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
US20250161466A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026028A2 (en) * 2000-09-26 2002-04-04 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
PT668933E (pt) 1992-11-19 2003-02-28 Anticancer Inc Utilizacao de metioninase como agente anti-tumor em qimioterapia anti-metionina
ATE361984T1 (de) 1992-12-04 2007-06-15 Me Medical Enzymes Ag Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie
DK75593D0 (enExample) 1993-06-25 1993-06-25 Novo Nordisk As
EP0776218A2 (en) * 1994-03-15 1997-06-04 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
DE851925T1 (de) 1995-09-21 2003-08-14 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
CA2315944A1 (en) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
CA2328614C (en) 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
DE60021760T2 (de) * 1999-12-09 2006-06-08 Chiron Corp., Emeryville Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
WO2002008293A2 (en) * 2000-07-25 2002-01-31 Immunomedics Inc. Multivalent target binding protein
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
WO2003072743A2 (en) 2002-02-26 2003-09-04 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
RU2324704C2 (ru) * 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
EP1576127A4 (en) 2002-11-14 2006-10-25 Scripps Research Inst CRYSTAL FORM OF FATTY ACID AMINE HYDROLASE (FAAH)
EP1636266A2 (en) * 2003-06-11 2006-03-22 Wyeth a Corporation of the State of Delaware Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026028A2 (en) * 2000-09-26 2002-04-04 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gordon V.Louie et al..Structural determinants and modulation of substrate specificity in phenylalanine-tyrosine ammonia-lyases.《Chem.Biol.》.2006,第13卷(第12期),1327-1338. *
赵健身.苯丙氨酸氨解酶.《天然产物研究与开发》.1993,第5卷(第4期),47-56. *

Also Published As

Publication number Publication date
LUC00133I2 (enExample) 2020-07-16
LTPA2019517I1 (lt) 2019-10-25
EP2657335A1 (en) 2013-10-30
SI2152868T1 (sl) 2015-12-31
LTC2152868I2 (lt) 2020-09-25
EP2152868B1 (en) 2015-09-02
MY151413A (en) 2014-05-30
MX2009012453A (es) 2010-01-25
IL202132A0 (en) 2010-06-16
EA018443B1 (ru) 2013-08-30
HRP20151268T1 (hr) 2015-12-18
WO2008153776A8 (en) 2009-07-30
WO2008153776A1 (en) 2008-12-18
TWI418633B (zh) 2013-12-11
AU2008263190B2 (en) 2014-04-17
CY2019039I1 (el) 2020-05-29
HUE025784T2 (en) 2016-05-30
JP2010529835A (ja) 2010-09-02
EA200970980A1 (ru) 2010-04-30
AR110834A2 (es) 2019-05-08
KR20150038753A (ko) 2015-04-08
TW200902052A (en) 2009-01-16
US7534595B2 (en) 2009-05-19
LUC00133I1 (enExample) 2019-10-16
CA2687450A1 (en) 2008-12-18
CY1116894T1 (el) 2017-04-05
BRPI0811267B1 (pt) 2020-11-10
CL2008001497A1 (es) 2009-01-09
ES2551315T3 (es) 2015-11-18
AR066716A1 (es) 2009-09-09
BRPI0811267B8 (pt) 2021-05-25
IL202132A (en) 2017-06-29
PL2152868T3 (pl) 2016-01-29
JP5670183B2 (ja) 2015-02-18
CN101842482A (zh) 2010-09-22
KR101603796B1 (ko) 2016-03-17
HK1135141A1 (zh) 2010-05-28
NO2019037I1 (no) 2019-10-16
CY2019039I2 (el) 2020-05-29
NL301011I2 (nl) 2020-05-13
BRPI0811267A2 (pt) 2014-10-07
US20080008695A1 (en) 2008-01-10
EP2152868A1 (en) 2010-02-17
KR20100024437A (ko) 2010-03-05
NL301011I1 (nl) 2019-10-16
CA2687450C (en) 2019-03-26
PT2152868E (pt) 2015-11-13
PE20090315A1 (es) 2009-03-19
AU2008263190A1 (en) 2008-12-18
HUS1900049I1 (hu) 2019-11-28
DK2152868T3 (en) 2015-11-16

Similar Documents

Publication Publication Date Title
CN101842482B (zh) 原核生物苯丙氨酸氨裂合酶的组合物及使用所述组合物的方法
US7531341B1 (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US20240035013A1 (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
US7553653B2 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
HK1225299A1 (en) Method for purifying prokaryotic phenylalanine ammonia-lyase variants
HK1135141B (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions
HK40081555A (en) Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
HK40008404A (en) Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
HK1177753A (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant